RogerHenderson
2021-11-22

Base on the BMO reported, which gave PFE an OUTPERFORM rating and a $60 price target based on 7.4 times estimated earnings for the next 12 months which is much better than MRK and most other large pharmas. It talked about COVID revenues as well as a well diversified approved drug portfolio. It also stressed a solid pipeline. So PFE still has more room to move up. Hold tight guys, still have profit in it.

$Pfizer(PFE)$

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法
1